Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Finished Goods (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Finished Goods for 3 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Finished Goods fell 1.49% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 1.49% year-over-year, with the annual reading at $1.5 million for FY2025, 1.49% down from the prior year.
  • Finished Goods for Q4 2025 was $1.5 million at Phathom Pharmaceuticals, down from $2.6 million in the prior quarter.
  • The five-year high for Finished Goods was $2.6 million in Q3 2025, with the low at $647000.0 in Q4 2023.
  • Average Finished Goods over 3 years is $1.5 million, with a median of $1.5 million recorded in 2025.
  • Peak annual rise in Finished Goods hit 177.27% in 2025, while the deepest fall reached 1.49% in 2025.
  • Over 3 years, Finished Goods stood at $647000.0 in 2023, then soared by 128.59% to $1.5 million in 2024, then dropped by 1.49% to $1.5 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $1.5 million, $2.6 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.